These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 22166048

  • 1. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M, Stoffel SA, Westerfeld N, Amacker M, Theisen M, Zurbriggen R, Pluschke G.
    Malar J; 2011 Dec 13; 10():359. PubMed ID: 22166048
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM, Miura K, Sullivan J, Long CA, Barnwell JW.
    Malar J; 2016 Mar 15; 15():159. PubMed ID: 26975721
    [Abstract] [Full Text] [Related]

  • 3. Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.
    Mamo H, Esen M, Ajua A, Theisen M, Mordmüller B, Petros B.
    Malar J; 2013 Feb 05; 12():51. PubMed ID: 23383869
    [Abstract] [Full Text] [Related]

  • 4. Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine.
    Tamborrini M, Mueller MS, Stoffel SA, Westerfeld N, Vogel D, Boato F, Zurbriggen R, Robinson JA, Pluschke G.
    Malar J; 2009 Dec 30; 8():314. PubMed ID: 20042100
    [Abstract] [Full Text] [Related]

  • 5. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas.
    Jepsen MP, Jogdand PS, Singh SK, Esen M, Christiansen M, Issifou S, Hounkpatin AB, Ateba-Ngoa U, Kremsner PG, Dziegiel MH, Olesen-Larsen S, Jepsen S, Mordmüller B, Theisen M.
    J Infect Dis; 2013 Aug 01; 208(3):479-88. PubMed ID: 23624363
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
    Mata E, Carcaboso AM, Hernández RM, Igartua M, Corradin G, Pedraz JL.
    Vaccine; 2007 Jan 15; 25(5):877-85. PubMed ID: 17070628
    [Abstract] [Full Text] [Related]

  • 7. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies.
    Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, Madsen SM, Druilhe P.
    Vaccine; 2004 Mar 12; 22(9-10):1188-98. PubMed ID: 15003647
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques.
    Kusi KA, Remarque EJ, Riasat V, Walraven V, Thomas AW, Faber BW, Kocken CH.
    Malar J; 2011 Jul 04; 10():182. PubMed ID: 21726452
    [Abstract] [Full Text] [Related]

  • 9. Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology.
    Okitsu SL, Mueller MS, Amacker M, Vogel D, Westerfeld N, Robinson JA, Zurbriggen R, Pluschke G.
    Hum Vaccin; 2008 Jul 04; 4(2):106-14. PubMed ID: 18382133
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.
    Sirima SB, Mordmüller B, Milligan P, Ngoa UA, Kironde F, Atuguba F, Tiono AB, Issifou S, Kaddumukasa M, Bangre O, Flach C, Christiansen M, Bang P, Chilengi R, Jepsen S, Kremsner PG, Theisen M, GMZ2 Trial Study Group.
    Vaccine; 2016 Aug 31; 34(38):4536-4542. PubMed ID: 27477844
    [Abstract] [Full Text] [Related]

  • 12. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
    Xue X, Ding F, Zhang Q, Pan X, Qu L, Pan W.
    Vaccine; 2010 Apr 19; 28(18):3152-8. PubMed ID: 20197139
    [Abstract] [Full Text] [Related]

  • 13. Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.
    Imam M, Devi YS, Verma AK, Chauhan VS.
    Clin Vaccine Immunol; 2011 Aug 19; 18(8):1221-8. PubMed ID: 21632889
    [Abstract] [Full Text] [Related]

  • 14. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
    Baptista BO, de Souza ABL, Riccio EKP, Bianco-Junior C, Totino PRR, Martins da Silva JH, Theisen M, Singh SK, Amoah LE, Ribeiro-Alves M, Souza RM, Lima-Junior JC, Daniel-Ribeiro CT, Pratt-Riccio LR.
    Malar J; 2022 Jan 04; 21(1):6. PubMed ID: 34983540
    [Abstract] [Full Text] [Related]

  • 15. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
    Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Birkett A, Dubovsky F, Tierney E, Gleiter CH, Boehmer G, Luty AJ, Ramharter M, Thornton GB, Kremsner PG, Nardin EH.
    Infect Immun; 2005 Jun 04; 73(6):3587-97. PubMed ID: 15908388
    [Abstract] [Full Text] [Related]

  • 16. Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana.
    Amoah LE, Nuvor SV, Obboh EK, Acquah FK, Asare K, Singh SK, Boampong JN, Theisen M, Williamson KC.
    Parasit Vectors; 2017 Aug 23; 10(1):395. PubMed ID: 28835262
    [Abstract] [Full Text] [Related]

  • 17. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
    Mistarz UH, Singh SK, Nguyen TTTN, Roeffen W, Yang F, Lissau C, Madsen SM, Vrang A, Tiendrebeogo RW, Kana IH, Sauerwein RW, Theisen M, Rand KD.
    Pharm Res; 2017 Sep 23; 34(9):1970-1983. PubMed ID: 28646324
    [Abstract] [Full Text] [Related]

  • 18. Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.
    Zhu D, McClellan H, Dai W, Gebregeorgis E, Kidwell MA, Aebig J, Rausch KM, Martin LB, Ellis RD, Miller L, Wu Y.
    Vaccine; 2011 May 09; 29(20):3640-5. PubMed ID: 21440641
    [Abstract] [Full Text] [Related]

  • 19. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
    Amoani B, Gyan B, Sakyi SA, Abu EK, Nuvor SV, Barnes P, Sarkodie-Addo T, Ahenkorah B, Sewor C, Dwomoh D, Theisen M, Cappello M, Wilson MD, Adu B.
    BMC Infect Dis; 2021 Apr 08; 21(1):332. PubMed ID: 33832450
    [Abstract] [Full Text] [Related]

  • 20. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
    Chitnis CE, Mukherjee P, Mehta S, Yazdani SS, Dhawan S, Shakri AR, Bhardwaj R, Gupta PK, Hans D, Mazumdar S, Singh B, Kumar S, Pandey G, Parulekar V, Imbault N, Shivyogi P, Godbole G, Mohan K, Leroy O, Singh K, Chauhan VS.
    PLoS One; 2015 Apr 08; 10(4):e0117820. PubMed ID: 25927360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.